# Lineage Cell Therapeutics Inc. (LCTX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Price:** $1.23 (+0.82%)

> Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel allogeneic, or off‑the‑shelf, cell therapies for serious neurological and ophthalmic conditions. The company leverages a proprietary cell-based technology platform and in-house development and manufacturing capabilities to design, produce, and test specialized human cells with anatomical and physiological functions similar to those found naturally in the body. These cells are generated from well-characterized pluripotent cell lines using directed differentiation processes, then transplanted to replace or support cells lost or damaged by degenerative disease, aging, or traumatic injury. Lineage Cell Therapeutics’ pipeline includes programs targeting dry age-related macular degeneration through retinal pigment epithelium cell replacement, spinal cord injury via oligodendrocyte progenitor cell therapy, oncology applications using dendritic cell vaccines, and additional preclinical candidates in hearing loss and vision restoration. Headquartered in Carlsbad, California, and founded in 1990, the company operates within the biopharmaceutical and medical research ecosystem, collaborating with larger industry partners to advance its cell therapy candidates toward broader clinical use.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/LCTX)